VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | AGMT_MM-1: the oral microbiome as a predictor of PFS in R/R myeloma

Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, discusses the AGMT_MM-1 trial (NCT02410694), which investigated the oral microbiome in patients with relapsed/refractory multiple myeloma treated with ixazomib, thalidomide and dexamethasone. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter